🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. PF-07850327 round

    Pfizer Ireland Pharmaceuticals Unlimited Company

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  3. PF-07868489

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  4. PF-07915503, PF-07915503, PF-07915503, Etrasimod Arginine Blue, PF-07915503

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  5. PF-08049820, PF-08049820, Placebo for PF-08049820

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  6. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  7. Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  8. Placebo for bms-986435-01

    Bristol-Myers Squibb / Pfizer EEIG

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  9. Placebo for pf-07328948 tablet (CCI) mg, Placebo for pf-07328948 tablet (CCI) mg

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Heart failure

    phase 2 small molecule active

    1 trial

  10. Placebo for ponsegromab (PF-06946860) solution for injection, Ponsegromab (PF-06946860)

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  11. Ponsegromab (PF-06946860), Placebo for ponsegromab (pf-06946860) solution for injection

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Heart failure

    phase 2 small molecule active

    1 trial

  12. Ritlecitinib Tosilate, Placebo for pf-06651600-15

    Pfizer Ireland Pharmaceuticals Unlimited Company

    HIDRADENITIS SUPPURATIVA

    phase 2 small molecule active

    1 trial

  13. Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  14. Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

  15. Sigvotatug vedotin, PF-08634404

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  16. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  17. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  18. The placebo for the pantoprazole sodium 40 mg, 20 mg, 10 mg and 5 mg delayed release granules in HPMC capsules, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE

    Pfizer Ireland Pharmaceuticals Unlimited Company

    EROSIVE ESOPHAGITIS

    phase 2 small molecule active

    1 trial

  19. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  20. farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  22. A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

    Bristol-Myers Squibb / Pfizer EEIG

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  23. A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources